Testing FXS0683 for Blood Cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called FXS0683 to treat certain blood cancers (like lymphomas and leukemias) that haven't responded to standard treatments. Researchers want to find the right dose and see if it helps patients whose cancer has come back or isn't responding to other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a blood cancer (B-cell lymphoma, myeloid cancer, or acute lymphoblastic leukemia) that didn't respond to standard treatments
- You are willing to have bone marrow samples taken and complete all study visits
- Your overall health is stable enough (ECOG performance status 0–2)
- You are not pregnant, not breastfeeding, and willing to use contraception if able to become pregnant
- You have not had other cancer treatments within 2–4 weeks before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
This early-phase trial tests whether SYHX1903 is safe and tolerable in people whose blood cancers have come back or did not respond. It may help by finding a workable dose and early safety signals for patients who have limited options.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.